Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Neurology ; 57(8): 1493-6, 2001 Oct 23.
Article in English | MEDLINE | ID: mdl-11673598

ABSTRACT

The authors report a 27-year-old woman with clinical, MRI, virologic, and CSF findings consistent with acute disseminated encephalomyelitis as a manifestation of primary HIV infection. Improvements in the clinical and MRI findings and a reduction in HIV RNA levels, both in plasma and in the CSF, were observed during highly active antiretroviral therapy.


Subject(s)
Encephalomyelitis, Acute Disseminated/virology , HIV Infections/complications , Adult , Antiretroviral Therapy, Highly Active , Encephalomyelitis, Acute Disseminated/pathology , Female , HIV Infections/drug therapy , HIV Infections/pathology , Humans , Magnetic Resonance Imaging , Prognosis
2.
Minerva Pediatr ; 46(4): 181-3, 1994 Apr.
Article in Italian | MEDLINE | ID: mdl-8084327

ABSTRACT

The authors report their experience on the use of oral suspension of Clarithromycin in respiratory infections in the pediatric age. Thirty-three patients affected by various infectious pathologies of the respiratory tract, treated with oral Clarithromycin at the dosage of 15 mg/kg/day, were studied. The therapeutic outcome was very encouraging, the drug well tolerated and without side effects.


Subject(s)
Clarithromycin/therapeutic use , Respiratory Tract Diseases/drug therapy , Administration, Oral , Child , Child, Preschool , Clarithromycin/administration & dosage , Humans , Infant , Treatment Outcome
3.
Riv Eur Sci Med Farmacol ; 14(4): 261-4, 1992.
Article in Italian | MEDLINE | ID: mdl-1306003

ABSTRACT

One-hundred and seventy-one cases of pertussis were observed at the Institute of Infections Diseases and at the 2nd Division of Infectious Diseases of the Policlinico Umberto I in Rome from January 1, 1987 to June 30, 1991. All subjects were treated according to a therapeutic protocol consisting of macrolides (erythromycin or myocamicin) at doses of 40-50 mg/die, betamethasone 0.1 mg/kg/die, specific immunoglobulin G at doses of 0.5 ml/kg repeated after 24 hours (new born babies and babies still unweaned) and oxygen therapy during the paroxystic fits. In 20 patients who were over the first year of life and who had serious asphyxiated fits, bronchodilators (trimetochinol or salbutamol) were added to the previous therapeutic scheme. Our data show both efficacy of therapeutic protocol and importance of early starting the treatment to shorten the length of disease, the strength of asphyxiated fits, and the risk of contagion.


Subject(s)
Whooping Cough/therapy , Adolescent , Anti-Bacterial Agents/therapeutic use , Child , Child, Preschool , Female , Humans , Immunotherapy , Infant , Infant, Newborn , Macrolides , Male , Oxygen Inhalation Therapy , Whooping Cough/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...